Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comekibart in Seasonal Allergic Rhinitis
NCT06846385Phase 3Recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of comekibart in seasonal allergic rhinitis (SAR), sponsored by Hunan Mabgeek Biotechnology. Started Mar 2025; status: recruiting.
02
Drugs
comekibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT06846385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846385.